Nxera Pharma to Receive $8.6 Million Milestone from Centessa

Yahoo Finance··JPUS·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Nxera Pharma announced it will receive an $8.6 million milestone payment from Centessa Pharmaceuticals, a wholly-owned subsidiary of Eli Lilly and Company, following late-stage development progress in its selective orexin receptor 2 agonist portfolio. The payment, triggered under Nxera's research collaboration with Centessa, will be recognized as revenue in the third quarter of the fiscal year ending December 31, 2026. Lilly completed its acquisition of Centessa on June 24, 2026, gaining ownership of the OX2R agonist pipeline, which includes clinical-stage molecules for sleep-wake and neurological disorders. Nxera retains rights to future development and commercialization milestones and royalties from the programs. CEO Christopher Cargill expressed satisfaction with the clinical progress and the portfolio's potential to address major unmet needs.

Impact on assets 3

Biotech & Genomic Medicine▲
Nxera Pharma Co., Ltd.
4565
▲ PositiveCapitalrelevance

Nxera receives an $8.6 million milestone payment, recognized as revenue in Q3 FY2026, with future milestones and royalties retained.

Health Care▲
Centessa Pharmaceuticals PLC ADR
CNTA
± Mixedrelevance

Centessa is the collaboration counterparty whose late-stage OX2R progress triggered the milestone, but the payment goes to Nxera, not Centessa.